drugset
drugset / Trial / NCT06049147

Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers

NCT06049147 ↗

Phase 1 Completed 72 enrolled Medibiofarma S.L.
RandomizedSequentialDouble-blindTreatment

Summary

This is a single center, randomised, double blind, placebo controlled clinical study to assess the safety and tolerability of MBF-015 in healthy volunteers.This clinical phase I trial is divided in two stages and involves, first, a single ascending dose (SAD) study in healthy young male volunteers and then a multiple ascending dose (MAD) study in healthy young men and woman. MBF-118 is developed for the treatment of multiple sclerosis.

Timeline

Start
2021-07-07
Primary completion
2023-08-24
Completion
2023-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject MBF-015 Unknown 4 mg Oral
Subject MBF-015 Unknown 8 mg Oral
Subject MBF-015 Unknown 16 mg Oral
Subject MBF-015 Unknown 32 mg Oral
Subject MBF-015 Unknown 64 mg Oral

Indications

No indication recorded.